Industry
Biotechnology
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Loading...
Open
2.63
Mkt cap
3.4M
Volume
18K
High
2.71
P/E Ratio
-0.14
52-wk high
22.35
Low
2.49
Div yield
N/A
52-wk low
2.18
Portfolio Pulse from Benzinga Newsdesk
August 09, 2023 | 1:30 pm
Portfolio Pulse from Benzinga Insights
August 09, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2023 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2023 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2023 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2023 | 12:06 pm
Portfolio Pulse from Happy Mohamed
July 05, 2023 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
June 01, 2023 | 12:52 pm
Portfolio Pulse from Benzinga Newsdesk
May 24, 2023 | 4:53 pm
Portfolio Pulse from Happy Mohamed
May 24, 2023 | 3:19 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.